Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists.

Rui Song, Hang Qian, Yunlian Wang, Qingmei Li, Dongfeng Li, Jishun Chen, Jingning Yang, Jixin Zhong, Handong Yang, Xinwen Min, Hao Xu, Yong Yang, Jun Chen

Journal of diabetes research 2022

filter terms:

The risk of cardiovascular diseases is closely related to diabetes. Macrovascular disease is the main cause of death and disability in patients with type 2 diabetes. In recent years, the glucagon-like peptide-1 receptor agonist (GLP-1RA), a new type of hypoglycemic drug, has been shown to regulate blood sugar levels, improve myocardial ischemia, regulate lipid metabolism, improve endothelial function, and exert a protective role in the cardiovascular system. This study reviewed the protective effects of GLP-1RA on the cardiovascular system. Copyright © 2022 Rui Song et al.

Citation

Rui Song, Hang Qian, Yunlian Wang, Qingmei Li, Dongfeng Li, Jishun Chen, Jingning Yang, Jixin Zhong, Handong Yang, Xinwen Min, Hao Xu, Yong Yang, Jun Chen. Research Progress on the Cardiovascular Protective Effect of Glucagon-Like Peptide-1 Receptor Agonists. Journal of diabetes research. 2022;2022:4554996